Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements

Schizophrenia Research

Volumn 62, Issue 3, 2003, Pages 245-250

  Zhang, Xiang Yang ^a,b,c   Zhou, Dong Feng ^a   Cao, Lian Yuan ^b   Chen, Da Chun ^b   Zhu, Feng Yan ^b   Wu, Gui Ying ^b  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Free radicals; Schizophrenia; Superoxide dismutase; Symptom; Tardive dyskinesia

Indexed keywords

SUPEROXIDE DISMUTASE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSKINESIA; FEMALE; GENDER; HEALTH; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MENTAL DISEASE; MENTAL PATIENT; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SCORING SYSTEM; SMOKING; SYMPTOM; TARDIVE DYSKINESIA;

EID: 0038460820     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00352-3     Document Type: Article

References (25)

1. Adler L.A., Peselow E., Rotrosen J., Duncan E., Lee M., Rosenthal M., Angrist B. Vitamin E treatment of tardive dyskinesia. Am. J. Psychiatry. 150:1993;1405-1407.
2. Adler L.A., Edson R., Lavori P., Peselow E., Duncan E., Rosenthal M., Rotrosen J. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol. Psychiatry. 43:1998;868-872.
3. Allen R.G. Oxygen-reactive species and antioxidant responses during development: the metabolic paradox of cellular differentiation. Proc. Soc. Exp. Biol. Med. 196:1991;117-129.
4. Cadet J.L., Lohr J.B. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann. N.Y. Acad. Sci. 570:1989;176-185.
5. Egan M.F., Hyde T.M., Albers G.W., Elkashef A., Alexander R.C., Reeve A., Blum A., Saenz R.E., Wyatt R.J. Treatment of tardive dyskinesia with vitamin E. Am. J. Psychiatry. 149:1992;773-777.
6. Furukawa K., Estus S., Fu W., Mark R.J., Mattson M.P. Neuroprotective action of cycloheximide involves induction of bcl-2 and antioxidant pathways. J. Cell Biol. 136:1997;1137-1149.
7. Hori H., Ohmori O., Shinkai T., Kojima H., Okano C., Suzuki T., Nakamura J. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology. 23:2000;170-177.
8. Lohr J.B. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch. Gen. Psychiatry. 48:1991;1097-1106.
9. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol. Bull. 31:1995;159-165.
10. Lohr J.B., Caligiuri M.P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J. Clin. Psychiatry. 57:1996;167-173.
11. Lohr J.B., Flynn K. Smoking and schizophrenia. Schizophr. Res. 8:1992;93-102.
12. Lohr J.B., Cadet J.L., Lohr M.A., Larson L., Wasli E., Wade L., Hylton R., Vidoni C., Jeste D.V., Wyatt R.J. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr. Bull. 14:1988;291-296.
13. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry. 28:1990;535-539.
14. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 19:1996;1-17.
15. Miller C.H., Simioni I., Oberbauer H., Schwitzer J., Barnas C., Kulhanek F., Boissel K.E., Meise U., Hinterhuber H., Fleischhacker W.W. Tardive dyskinesia prevalence rates during a ten-year follow-up. J. Nerv. Ment. Dis. 183:1995;404-407.
16. Morgenstern H., Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. Arch. Gen. Psychiatry. 50:1993;723-733.
17. Peet M., Laugharne J., Rangarajan N., Reynolds G.P. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int. Clin. Psychopharmacol. 8:1993;151-153.
18. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot. Essent. Fat. Acids. 55:1996;33-43.
19. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry. 39:1982;486-487.
20. Schwartz P.J., Coyle J.T. Effects of overexpression of the cytoplasmic copper-zinc superoxide dismutase on the survival of neurons in vitro. Synapse. 29:1998;206-212.
21. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview for DSM-III-R - Patient Version 1.0 (SCID-P). 1990;American Psychiatric Press, Washington, DC.
22. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry. 155:1998;1207-1213.
23. Wengenack T.M., Curran G.L., Poduslo J.F. Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia. Brain Res. 754:1997;46-54.
24. Yamada K., Kanba S., Anamizu S., Ohnishi K., Ashikari I., Yagi G., Asai M. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol. Med. 27:1997;1223-1225.
25. Zhang X.Y., Zhou D.F., Su J.M., Zhang P.Y. The effect of extract of Ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with schizophrenia. J. Clin. Psychopharmacol. 21:2001;85-88.